| Year |
Citation |
Score |
| 2011 |
Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, Leon MB. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). Jacc. Cardiovascular Interventions. 4: 543-50. PMID 21596327 DOI: 10.1016/j.jcin.2010.12.014 |
0.306 |
|
| 2010 |
Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas JS, Ball MW, Caputo RP, Jain A, Tolleson TR, Reen BM, ... ... Fitzgerald PJ, et al. A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions. 12-Month Outcomes From the ENDEAVOR IV Trial Journal of the American College of Cardiology. 55: 543-554. PMID 20152559 DOI: 10.1016/j.jacc.2009.08.067 |
0.304 |
|
| 2009 |
Verheye S, Agostoni P, Dawkins KD, Dens J, Rutsch W, Carrie D, Schofer J, Lotan C, Dubois CL, Cohen SA, Fitzgerald PJ, Lansky AJ. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial Jacc: Cardiovascular Interventions. 2: 205-214. PMID 19463427 DOI: 10.1016/j.jcin.2008.12.011 |
0.306 |
|
| 2007 |
Abizaid A, Lansky AJ, Fitzgerald PJ, Tanajura LF, Feres F, Staico R, Mattos L, Abizaid A, Chaves A, Centemero M, Sousa AG, Sousa JE, Zaugg MJ, Schwartz LB. Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent. The American Journal of Cardiology. 99: 1403-8. PMID 17493469 DOI: 10.1016/j.amjcard.2006.12.064 |
0.315 |
|
| Show low-probability matches. |